Filing Flows › Comparisons › EDIT vs VXRT
Editas Medicine vs Vaxart: EDIT and VXRT compared
Editas Medicine is the larger company: $11.9M of revenue in its latest quarter (Q2 2026) against $10.6M for Vaxart (Q3 2026). Editas Medicine is growing faster (+232% against -85% a year earlier). Editas Medicine is more profitable, with an operating margin of -156.0% against -162.7%.
Where the money goes: EDIT and VXRT
Editas Medicine (EDIT) · Q2 2026
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.
Vaxart (VXRT) · Q3 2026
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
| Editas Medicine (EDIT) | Vaxart (VXRT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $11.9M | $10.6M |
| Revenue growth, Y/Y | +232% | -85% |
| Operating margin | -156.0% | -162.7% |
| Net earnings | −$18.2M | −$17.7M |
| Net margin | -153.3% | -166.6% |
| Operating cash flow | −$29.6M | $1.4M |
| Free cash flow | — | $1.1M |
Where the revenue comes from
Vaxart
- Government Contract: $7.5M (71%)
- Collaboration Revenue: $2.9M (28%)
- Non Cash Royalty Revenue: $154K (1%)
Questions
Which is bigger, Editas Medicine or Vaxart?
Editas Medicine is the larger company: $11.9M of revenue in its latest quarter (Q2 2026) against $10.6M for Vaxart (Q3 2026).
Is Editas Medicine or Vaxart growing faster?
Editas Medicine is growing faster (+232% against -85% a year earlier).
Which is more profitable, Editas Medicine or Vaxart?
Editas Medicine is more profitable, with an operating margin of -156.0% against -162.7%.
More: Editas Medicine earnings · how Editas Medicine makes money · Vaxart earnings · how Vaxart makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.